Comparative Pharmacology
Head-to-head clinical analysis: PREVACID NAPRAPAC 500 COPACKAGED versus PROTONIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREVACID NAPRAPAC 500 COPACKAGED versus PROTONIX.
PREVACID NAPRAPAC 500 (COPACKAGED) vs PROTONIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lansoprazole inhibits gastric acid secretion by irreversibly binding to the H+/K+ ATPase (proton pump) in gastric parietal cells. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
Proton pump inhibitor that inhibits the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of gastric acid secretion.
One tablet of naproxen 500 mg and one capsule of lansoprazole 15 mg taken together orally once daily. Naproxen component: 500 mg orally twice daily. Lansoprazole component: 15 mg orally once daily.
40 mg orally once daily; alternatively, 40 mg IV once daily for 7-10 days.
None Documented
None Documented
Naproxen: 12–17 hours (mean ~14 h), prolonged with renal impairment. Esomeprazole: 1–1.5 hours (increase to 2–3 h with CYP2C19 poor metabolizers or hepatic impairment).
Terminal elimination half-life is about 1–2 hours in healthy individuals; in CYP2C19 poor metabolizers or hepatic impairment, half-life may increase up to 3–6 hours, but clinical impact is minimal due to irreversible binding to H+/K+-ATPase.
Naproxen: 95% renal (primarily as unchanged drug and metabolites, including 6-O-desmethyl naproxen), <5% biliary/fecal. Esomeprazole: 80% renal (as metabolites, primarily hydroxyesomeprazole and desmethyl-esomeprazole, with ~1% unchanged), 20% fecal (via bile).
Approximately 80% of a dose is excreted as metabolites in urine, with the remainder (≈20%) in feces via biliary elimination.
Category C
Category C
Proton Pump Inhibitor/NSAID Combination
Proton Pump Inhibitor